Evaluation of the efficacy of celecoxib in the treatment of acute mania

Celecoxib added to mood stabilizer for treating acute mania: A randomized, double-blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200306046708N1

Enrollment

Registered

2020-03-28

Start date

2633-12-15

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mania. Bipolar disorder, current episode manic without psychotic features

Interventions

Intervention 1: Intervention group: Valproate plus celecoxib 400 mg daily (200 mg twice daily). Intervention 2: Control group: Valproate plus placebo is given twice daily.

Eligibility

Sex/Gender

All

Age

20 Days to 60 Days

Inclusion criteria

Inclusion criteria: Eligible for Mania Course based on DSM IV - TR Diagnostic Criteria No other supportive therapy or use of cognitive therapy. Age between 18 and 65 years. Fill out the informed consent form.

Exclusion criteria

Exclusion criteria: Causing side effects. Willingness to exit the study Unavailability of the patient.

Design outcomes

Primary

Measure	Time frame
Mania. Timepoint: baseline, 4, 8, 12 weeks. Method of measurement: young questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNajmeh Shahini

Mashhad University of Medical Sciences

najmeh.shahini@gmail.com+98 17 3215 5653

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026